Clinical Trials Browser

Interventional × Acromegaly × Clear all

Gastro-enteropancreatic neuroendocrine tumor, Acromegaly

NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT02419664 2022-03-31

Ga-68-DOTATOC -PET in the Management of Pituitary Tumours

Phase 3 Terminated

22 enrolled

Endocrine

Acromegaly, Pituitary Diseases, Pituitary Neoplasms

NCT01861717 2021-09-30

A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.

Phase 4 Terminated

4 enrolled 5 charts

Endocrine

Acromegaly, Gigantism, Pituitary Neoplasms

NCT00446082 2020-12-21

Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

Phase 1 Completed

85 enrolled

Endocrine

Acromegaly, Carcinoid Tumor

NCT04529356 2020-08-27

The TMS Treatment for Postoperative Headache in GH Tumor

Phase NA Unknown

200 enrolled

Endocrine

Acromegaly, Headache, Pituitary Neoplasms

NCT02354508 2019-12-10

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Phase 3 Completed

123 enrolled 27 charts

Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01673646 2019-09-16

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Phase 2 Completed

33 enrolled 24 charts

Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01137682 2018-04-05

PAOLA

Phase 3 Completed

198 enrolled 17 charts

Endocrine

Acromegaly, Pituitary Neoplasms

NCT03439709 2018-03-01

MERGE

Phase 3 Unknown

90 enrolled

Endocrine

Acromegaly, Pituitary Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

NCT02299089 2017-12-15

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Phase 2 Completed

12 enrolled 18 charts

EndocrineNET

Acromegaly, Neuroendocrine Tumors, Serotonin Syndrome

NCT00376064 2017-03-06

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Phase 4 Completed

20 enrolled

CNSEndocrine

Acromegaly, Brain Neoplasms, Pituitary Neoplasms

NCT00171886 2017-02-24

Octreotide Efficacy and Safety in First-line Acromegalic Patients

Phase 4 Completed

20 enrolled

Acromegaly

NCT01029275 2014-07-31

SAPORO

Phase NA Completed

89 enrolled

Endocrine

Acromegaly, Pituitary Neoplasms

NCT00001860 2008-03-04

Sandostatin LAR Depot vs. Surgery for Treating Acromegaly

Phase 2 Completed

5 enrolled

Endocrine

Acromegaly, Pituitary Neoplasms

NCT00017927 2008-03-04

A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome

Phase 3 Completed

10 enrolled

Acromegaly, Adenoma, Fibrous Dysplasia, Polyostotic, Hyperplasia

NCT00627796 2008-03-03

ATG1line

Phase 4 Completed

27 enrolled

Acromegaly, Neoplasms

NCT00461149 2007-04-17

HDacro

Phase 4 Completed

50 enrolled

Endocrine

Acromegaly, Pituitary Neoplasms

Clinical Trials

OXTEND-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Ga-68-DOTATOC -PET in the Management of Pituitary Tumours

A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.

Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease

The TMS Treatment for Postoperative Headache in GH Tumor

Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

PAOLA

MERGE

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Octreotide Efficacy and Safety in First-line Acromegalic Patients

SAPORO

Sandostatin LAR Depot vs. Surgery for Treating Acromegaly

A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome

ATG1line

HDacro